The test, which runs on the Swiss company's high-throughput MosaiQ System, detects 15 different autoantibodies.

AliveDx’s CE mark for the systematic autoimmune rheumatic disease (SARD) assay marks its fifth approval in the past 18 months.

AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Produc ...